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What is already known about this subject? 
1) Insulin therapy is the most effective therapy to lower HbA1c levels but is well recognised 
to be associated with weight gain  
2) Weight gain and obesity is a recognized risk factor for the development of type 2 diabetes, 
and adverse cardiovascular outcomes. 
 
What does this study add? 
1) Despite the well-recognised correlation between obesity, exogenous hyperinsulinaemia 
and CV, there is little direct evidence relating to the impact of baseline obesity on metabolic 
and mortality outcomes following insulin initiation in routine clinical practice.   
2) In the short term, increasing level of obesity is significantly associated with reduced 
likelihood of achieving target HbA1c levels, but this observation was not significant in the 
longer term  
3) Patients with morbid obesity who are started on insulin therapy is associated with a 30% 
increased risk of developing adverse cardiovascular outcomes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abstract 
 
Objectives: Insulin therapy induces weight gain but whether it causes long term adverse 
metabolic and CV outcomes in obese patients remains unclear. 
Methods: A retrospective cohort study of 12,725 insulin initiators with T2D derived from UK 
General Practices. Multivariate linear, logistic regression analyses and Cox proportional hazard 
models were used to estimate HbA1c, BMI, risk of composite CV events between baseline 
BMI categories at 5 years. 
Results: Mean age was 58.6±13.8 years. The proportion of patients achieving HbA1c targets 
decreased across increasing BMI categories at 6 and at 12 months; p=0.0001, but not significant 
beyond 24 months. 1,095 composite events of all-cause mortality, non-fatal stroke and MI 
occurred with an adjusted hazard risk (aHR) relative to normal of : (1.10; 95%CI: 0.90-1.35) 
in the overweight, (1.05; 95%CI: 0.86-1.29) in the obese class I, (1.03; 95%CI: 0.83-1.29) in 
the obese class II and (1.30; 95%CI: 1.02-1.66) in the obese class III BMI categories.  
Conclusion: Among patients with T2D insulin initiators, obesity adversely influence HbA1c 
up to 12 months, but not beyond 24 months and is associated with a decrease in BMI compared 
to non-obese groups. Morbidly obese patients initiating insulin have 30% increased risk of 
composite CV events after 5 years. 
Introduction:  
In the UK, obesity is estimated to affect 1 in every 4 adults[1], is prevalent in patients with type 
2 diabetes (T2D) worldwide [2,3] and is recognised to be associated with adverse 
cardiovascular (CV) events including mortality[4]. The therapeutic management of T2D aims 
at maintaining good glycaemic control in order to minimise long-term vascular complications 
but in the obese population, balancing the appropriate choice of therapy with the unintended 
effects such as weight gain presents a dilemma and therefore needs to be individualised [5]. 
Insulin therapy is the most effective therapy to lower Glycated Haemoglobin (HbA1c) levels 
but is well recognised to be associated with weight gain [6]. In the United Kingdom Prospective 
Diabetes Study (UKPDS), patients in the intensive intervention cohort was observed to gain 
approximately 5 kg during the 10-year follow-up period, with most of this gain occurring in 
the first 12 months. [7] We and others have also shown that in routine clinical practice, the 
effectiveness of insulin therapy to lower HbA1c levels is dependent on patients’ baseline 
weight [8,9], and is speculated to be due to insulin-induced weight gain resulting in an increase 
in the amount of insulin required to control hyperglycaemia [10,11] at the expense of further 
weight gain, possible poor treatment compliance and increased insulin resistance. 
Despite the well-recognised correlation between obesity, exogenous hyperinsulinaemia and 
CV risk [12], there is little direct evidence relating to the impact of baseline obesity on mortality 
outcomes following insulin initiation in routine clinical practice.  However, there is indirect 
evidence that weight gain does adversely affect CV risk. The ACCORD study designed to 
investigate whether an aggressive therapeutic strategy to achieve tight glucose target (HbA1c 
<6.5%) would reduce CV events surprisingly showed an increased mortality in the intensively 
treated group [13], with weight gain by more than 10kg occurred in 27.8% of the intensively 
treated patients compared with 14.1% in the standard therapy. While no causal relationship 
between  obesity and adverse CV outcomes can be assumed, other retrospective studies have 
shown that people with diabetes who actively lose weight improve not only their risk profile 
[14–16] but also survival rate. Previous similar studies focusing on the association between 
obesity at insulin initiation were limited by either by their choice of patients as in the UKPDS 
which used predominantly obese patients; [7] study population size; [6]; the exclusion of 
younger patients with T2D, short follow up period, or failure to adjust for important risk factors 
associated with obesity [17].  
To our knowledge, no real-world study has explored the long-term effects of obesity at insulin 
initiation on metabolic and CV outcomes. So, we aimed therefore to investigate the association 
between obesity, metabolic outcomes (HbA1c and weight), CV events and mortality in patients 
with T2D who initiated insulin therapy. 
Methods:  
Study Design and Data Source: 
This was a retrospective cohort study using data derived from the UK anonymised longitudinal 
electronic Primary Care data called The Health Improvement Network (THIN). This database 
has details of over 12.4 million patients (3.61 million currently active) from about 587 UK 
general practices. It has been validated and shown to be representative of the UK population in 
terms of demography, life-event rates and other health-related events; and has been extensively 
used in diabetes-related researches. [18-20] Anonymised records on all insulin users with type 
2 diabetes (T2D) between December 1, 2007 and May 31, 2014 were obtained and data on 
HbA1c levels, height, weight, socio-demographic variables, prescriptions of glucose-lowering 
medications, other medication prescriptions, and co-morbidities between 180 days before 
insulin initiation to 5 years after initiation were extracted. 
Selection Criteria and Study Population: 
The patient cohort was selected based on the following criteria at the index date of insulin 
initiation: age ≥ 18 years; records of diagnosis of T2D (identified by their appropriate ICD-10 
codes) made a minimum of 180 days before index date and continuous prescription of insulin 
beyond 180 days after index date. Patients with identifiable ICD-10 codes for type 1 diabetes, 
gestational or other forms of diabetes, or with no identifiable continuous insulin prescription 
in their records were excluded. Insulin regimens are classed as premixed insulin (combination 
of short acting and long acting insulin in a prefilled pen) and basal bolus insulin (combination 
of any long acting insulin injected any time with at least one short acting insulin with meal) 
Study Exposure and Outcomes: 
The main exposure was the baseline BMI [weight (kg) / (height (m) x height (m))]. This was 
assessed from 0 to 90 days before the index date. BMI was classified thus: normal (BMI ≤ 
24.9kg/m2), overweight (BMI: 25.0 - 29.9kg/m2), obese/obese class I (BMI: 30.0 – 34.9kg/m2), 
clinically obese/obese class II (BMI: 35.0 – 39.9kg/m2) and morbidly obese/obese class III 
(BMI: ≥40.0kg/m2). 
The primary outcomes were i) changes in HbA1c, weight and BMI from baseline to 6, 12, 24, 
36, 48 and 60 months post index date; and ii) proportion of patients achieving a target HbA1c 
of ≤ 7.5% at these time intervals, stratified by BMI at index date.  Post-index date HbA1c, 
weight and BMI values were assessed at 6 months and later at yearly intervals till a maximum 
of 5 years after index date. Where more than one recording of a variable was noted within each 
time interval, the mean value was computed and recorded for that review date. Secondary 
outcome was the risk of a three-point composite of Major Adverse Cardiovascular Events 
(MACE), comprising of non-fatal myocardial infarction (MI), non-fatal stroke and all-cause 
mortality between the baseline BMI categories. In estimating this risk, patients were followed 
up from the point of insulin initiation (index date) and censored at the earliest occurrence of 
any of the following outcomes - discontinuation of insulin, occurrence of MACE, loss to 
follow-up, and at the end of the study at 5 years. The time (t) to any of these outcomes was 
determined for each patient, as well as the event of MACE (d) which occurred within this time 
interval. These were fitted in a Cox regression model. 
Covariates: 
Significant a priori confounders which could impact on glycaemic control, change in weight 
and BMI, and the risk of MACE were extracted at baseline and adjustment was made for these 
in the multivariate linear and Cox regression models. These include demographic variables as 
age, gender, socioeconomic status (derived by the Townsend deprivation (21) scores and 
ranked in quintiles from the least, to the most deprived area), alcohol (drinker defined as 
currently consuming any amount of alcohol per week) and smoking status. Others were clinical 
measures as systolic and diastolic blood pressure, diabetes duration before index date, duration 
of use of other glucose-lowering therapies (GLTs), use of antihypertensives and lipid-lowering 
therapies (LLTs), co-morbidity status and laboratory measures as creatinine level, lipid-profile 
(total cholesterol, high density lipoprotein, low density lipoprotein, and triglycerides), 
glomerular filtration rates (eGFR), and albumin level.  
 
Statistical Methods 
 A small proportion of patients had missing records for HbA1c, weight and height at different 
time intervals. These variables were uniformly distributed and completely missing at random. 
Multiple imputations using the chained equation (MICE) model was used to account for these 
missing data and the imputed (complete) data were used for all analyses. The baseline 
characteristics of the study cohort was first summarised as the mean (with standard deviation) 
and as absolute values (with proportions) stratified by BMI category at baseline.  
A univariate linear regression model was used to test the association between these baseline 
covariates and the study exposure and outcomes in order to adjust for any confounding effect 
they may have on the study outcomes. Covariates which were found to be significantly 
associated (p < 0.05) with the study exposure and outcomes were selected for inclusion in the 
multivariate model. So, for the primary outcomes of changes in HbA1c, weight and BMI, a 
multivariate repeated-measures linear regression model was fitted with their values at 6, 12, 
24, 36, 48 and 60 months to estimate changes from index date. Pearson’s Chi-square test was 
used to estimate the proportion achieving an HbA1c target of ≤ 7.5% at each time interval. 
To estimate the hazard of MACE, crude and adjusted Kaplan–Meier estimates of survival 
functions between the BMI categories were calculated and the log-rank test was used to 
compare the equality of the survival curves between them. From these survival functions, we 
computed the absolute reduction in the probability of the incidence of the all-cause mortality 
within a 5-year follow-up. Finally, a Cox proportional hazard model to estimate the marginal 
and adjusted hazard of MACE in all the BMI groups (treated groups), compared to the normal 
BMI group. Any violations in the proportional hazards assumptions were confirmed with 
Schoenfeld residuals tests.   
Sensitivity and Subgroup analyses 
To explore the impact the missing values may have on the overall outcome and assess the 
robustness of our imputation, all the analyses were repeated in the dataset with missing values 
and the study outcomes compared. Also, subgroup analyses were done for the individual 
components of MACE, as well as a composite of CV events (non-fatal MI or stroke). 
In all the models, the point estimates were estimated with 95% confidence intervals (CI) at the 
conventional statistical significance level of < 0.05 while all analyses were conducted using 
Stata Software, version 14 (StataCorp. Stata Statistical Software: Release 14. College Station, 
TX: StataCorp LP. 2015).
Results:  
Baseline demographics: 
The study population comprised 12,725 patients with T2D after the application of the inclusion 
and exclusion criteria on the initial 19,808 patients identified in the THIN dataset (Figure 1). 
There was a greater proportion of males in the normal BMI category and higher proportion of 
females in the obese class III BMI category (p < 0.0001). Patients in the normal BMI category 
were older while those in the obese class III were younger. Conversely, baseline HbA1c and 
systolic blood pressure were highest and lowest in the obese class III and normal BMI 
categories respectively (Table 1). 
Association between BMI on insulin initiation and glycaemic control. 
A summary of the proportion of patients achieving the National Institute of Health and Care 
Excellence (NICE) target of ≤7.5% (58 mmol/mol) and the odds of attaining this target 
compared to the normal BMI category is shown in Table 2. Compared to the normal BMI 
group, the odds of achieving the target HbA1c significantly declined across all rising BMI 
levels at 6 and 12 months. On the long term, however, there was no significant difference in 
the proportion achieving this target beyond 24 months, neither was any significant trend 
observed. 
Figure 2 showed the mean change in HbA1c from baseline in all BMI categories. Overall, there 
was a significant reduction in HbA1c- the greatest reduction was seen in the normal BMI 
category from 6 to 24 months, but beyond this period, the morbidly obese category recorded 
the greatest reduction. Following adjustment for age, gender, baseline HbA1c and duration of 
diabetes, when compared to the normal BMI group, the reductions in HbA1c at 6 months were 
0.10% (95%CI: -0.01, 0.21; p=0.075) in the overweight; 0.19% (95%CI: 0.08, 0.29; p<0.001) 
in obese class I; 0.21% (95%CI: 0.10, 0.32; p<0.001) in obese class II; and 0.29% (95%CI: 
0.17, 0.42; p<0.001) greater in the class III obese groups. At 12 months, the adjusted 
differences were slightly reduced to 0.08% (95%CI: -0.02, 0.19; p=0.119) in the overweight; 
0.17% (95%CI: 0.06, 0.27; p=0.001) in obese class I; 0.19% (95%CI: 0.08, 0.30; p=0.001) in 
obese class II; and 0.25% (95%CI: 0.13, 0.38; p<0.001) greater in the class III obese groups. 
Beyond 24 months, we failed to show statistical significance in the mean difference in HbA1c 
change between the BMI groups; such that at 60 months, the mean difference was 0.08% 
(95%CI: -0.09, 0.25; p=0.356) in the overweight; 0.05% (95%CI: -0.12, 0.21; p=0.807) in 
obese class I; 0.06% (95%CI: -0.11, 0.24; p=0.475) in obese class II; and -0.002% (95%CI: -
0.20, 0.19; p=0.981) greater in the class III obese groups.   
Association between BMI at baseline and changes in weight and BMI 
There was a consistent significant increase in weight and BMI in the normal and overweight 
categories throughout the study duration, while the other categories experienced a decrease (p 
<0.00001 in all). Patients in the normal and overweight categories experienced increases in 
mean weight from 71.8kg and 81.5kg respectively at 6 months, to 80.7kg and 85.3kg (p < 
0.0001) at 60 months; but in the obese (classes I to III) categories, there was a significant 
reduction in weight from baseline at each study timeline (e.g. from 115.1kg at 6 months to 
103.5kg at 60months (p<0.0001) in the morbidly obese category). Similarly,  BMI increased 
from 23.3kg/m2 and 28.3kg/m2 at 12 months in the normal and overweight categories 
respectively to 28.2kg/m2 and 30.5kg/m2 respectively at 60months (p<0.0001) but other BMI 
categories had a significant decrease in BMI (Table 3). 
The mean coefficient of change in weight compared to the normal BMI category showed 
greater reduction in weight and BMI across all the BMI categories, compared to the normal 
category at all study timelines (LRT p-values were <0.00001 in all). There was a significant 
trend (p <0.0001) across the BMI categories. So, for each level of baseline BMI, there was a 
reduction in weight and BMI. For instance, our findings at 12 months shows that for each level 
increase in BMI category, there was a reduction of 1.4kg (95%CI: -1.5, -1.3; p <0.0001) in 
weight and 0.62kg/m2 (95%CI: -0.67, -0.58; p <0.0001) in BMI.  
Figure 3 summarise the mean change in BMI within the baseline BMI categories by the study 
timelines. The funnel-shape figure depict the different change patterns between the normal and 
overweight BMI categories vs the Obese (Classes II and III). The obese class I category 
maintained almost a plateau.  At 60 months, the greatest reductions in weight and mean BMI 
were in the obese class III category (losing 12.91kg and 5.66kg/m2 respectively from baseline) 
as against the normal category which recorded the greatest gain of 11.00 kg in weight and 
6.32kg/m2 in BMI from baseline.  
 
Risk of Major Adverse Cardiovascular Event (MACE)  
The mean follow-up duration was 4.38 years with a total follow-up of 49,516 person-years. 
There is no significant difference in survival between the baseline BMI categories at 5years 
(log-rank test p-value = 0.228). There were 1,095 composite events of MACE, with a crude 
event rate of 22.1 per 1,000 person-years (95%CI: 20.8, 23.5). BMI at insulin initiation was 
associated with a 10% [aHR: 1.10 (0.90 – 1.35)]; 5% [aHR: 1.05 (0.86 – 1.29)]; 3% [aHR: 1.03 
(0.83 – 1.29)]; and 30% [aHR: 1.30 (1.02 – 1.66)] higher risk of MACE in the overweight, 
obese, clinically obese and morbidly obese categories respectively, compared to the normal 
BMI category after adjusting for age, gender, use of LLTs and antihypertensives, comorbidities 
of heart failure and coronary heart disease, albumin, GFR, lipid profile (total cholesterol, low 
density lipoprotein cholesterol, triglyceride, high density lipoprotein cholesterol) and the use 
of GLP-1RA (Table 4).  
Subgroup Analysis: In the adjusted model, the risk of all-cause mortality was 9% [aHR: 1.09 
(0.81 – 1.45)]; 12% [aHR: 1.12 (0.84 – 1.49)]; 31% [aHR: 1.31 (0.96 – 1.77)]; and 75% [aHR: 
1.75 (1.26 – 2.43)] higher risk of MACE in the overweight, obese, clinically obese and 
morbidly obese categories respectively while the risks of a composite CV event were 25%, 
21%, the same, and 34% higher compared to patients with normal BMI at baseline. 
Discussion: 
Several conclusion could be derived from this observational study obtained from a large 
longitudinal real world data. Firstly, HbA1c reduction was reduced irrespective of baseline 
HbA1c with a marginal greater Hba1c reduction in the normal/overweight weight group in the 
first 2 years and obese group at 3 years of insulin treatment. Secondly, insulin induced 
significant weight gain among normal and overweight individuals but a paradoxical weight 
loss in the obese individual. Thirdly, the observed weight loss in the obese group was consistent 
over 12, 24 and 36 months of insulin treatment; and lastly obese patients, especially stage III 
obesity, was associated with an increased risk of mortality at 5 years of follow up. This study 
provides reassurance of the efficacy of insulin treatment in patients with T2D, irrespective of 
their baseline BMI, but highlight the high mortality risk for the obese patients with T2D. 
Our findings above are robust, and are supported by separate analyses to explore possible 
confounders and via sensitivity analysis. This is further supported by consistent findings in 
patients from the entire cohort. The level of HbA1c and CV risk profile (e.g. lipid, blood 
pressure) were clinically similar across all weight change categories. This findings of this study 
was in concordance with a previous study using a US-based electronic medical record which 
reported a reduction in HbA1c was associated with progressively less weight gain as baseline 
BMI rose. [22]. The inference from that study that the lesser weight gain seen in obese patients 
was due to the use of less intensive insulin therapy may also apply to this cohort, although 
interestingly, we observed greater HbA1c reduction and paradoxical greater weight loss in the 
obese group, compared with the normal and overweight group at 36 months of insulin 
initiation. When adjusted for different confounder, we observed an overall greater HbA1c 
reduction in in the normal weight group and lesser weight in the overweight and obese group.  
Although we observed the association between higher mortality rate with baseline obesity at 
insulin initiation, our study did not infer a causative role of insulin treatment in inducing the 
adverse mortality outcome in obese patients. Indeed, increased body weight among obese 
individuals per se is recognised to lead to worsening of cardiovascular risk factors [16,17,23] 
and in a prospective study of more than 17,000 middle-aged patients, obese patients with 
diabetes had a 3-fold greater risk of mortality compared to non-obese patients with diabetes, 
independent of their glucose lowering treatment [24]. Whether insulin induced weight gain is 
associated with adverse CV outcome remains unknown because robust large scale clinical trials 
such as UKPDS [7], ADVANCE [25] and ACCORD [13] study did not stratify their CV 
outcomes by weight-loss or weight-gain, for any given level of glycaemic control. However, 
in a post hoc analysis of the ACCORD study, patients who were inadequately controlled at 
baseline and received intensive glucose lowering strategy but still had suboptimal glucose 
control (HbA1c >7%; >53 mmol/mol) experienced higher mortality rate [26]. This observation 
suggest patient-factors associated with persistently high HbA1c, despite intensive treatment, 
appear to be the most important determinant of increased mortality risks. To this end, an 
important confounder that needs to be considered in our observation is that insulin-induced 
weight gain suggest patients’ compliance to insulin treatment intensification and thus a 
surrogate marker of compliance to holistic care and treatment.  
Thus the observation from this study that obese patients experienced relative weight loss and 
less HbA1c reduction (compared to the normal and overweight group) could potentially imply 
a less compliance or less aggressively managed patients. While compliance to insulin therapy 
may also be a factor in this observation, it might be conceivable that overweight patients were 
provided with more detailed advice regarding strategies to lose weight and/or a referral to 
dietitian, due to anticipated weight gain due to insulin, than individuals who are underweight 
or have normal weight. However, this observation only hold valid in the first 24 months of 
treatment, because at 36 months of treatment, there appears to be a greater relating HbA1c 
reduction in the obese group, compared with normal or overweight. Nevertheless, we contend 
that that failure to achieve HbA1c reduction, despite optimal glucose lowering treatment, in 
obese patients should trigger clinicians to intensify cardiovascular risk reduction strategies. 
Our analyses were subject to a number of limitations that are inherent to observational studies. 
Firstly, as previously discussed, we cannot ascertain treatment compliance. Also, some factors 
like lifestyle and dietary intervention may influence our findings. We were also not able to 
obtain the longitudinal insulin doses, an important predictor of insulin-induced weight gain. 
[27,28]. Difference in the use of different glucose lowering therapy is large. This however 
reflects the current preference of glucose lowering therapy in UK primary care, i.e. a high 
preference for metformin and sulfonylurea, but less experience with novel therapies like DPP4 
inhibitor, GLP-1 and SGLT inhibitor). In addition, the long duration of diabetes may also 
account for differences in the use of GLT in this study. This may be since our aim was to look 
at status of baseline weight per se on metabolic and CV outcomes, we would argue that this 
should not influence the robustness of our findings. Although we could not account for other 
potential residual confounders such, indications for intensification treatments, markers of β-
cell deterioration, doses of lipid lowering or antihypertensive therapy and frequency of 
hypoglycaemia, we were able to account for differences in the observed covariates and used 
robust analytical techniques to control confounding that may bias the results of the estimated 
treatment effects. 
In conclusion, we observed that while insulin treatment is associated with weight gain, baseline 
weight confers only a marginal influence on its efficacy in achieving HbA1c target. 
Nevertheless, obese patients at the time of insulin initiation appear to be at high risk of 
mortality. While these findings should provide important reassurance among patients with T2D 
who gained weight following insulin treatment in routine clinical practice, it also highlights the 
high mortality risk of obese people with T2D. 
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Table 1: Baseline characteristics of the study population 
 
Normal 
(n=1665) 
Overweight 
(n=3022) 
Obese Class I 
(n=3712) 
Obese Class II 
(n=2637) 
Obese Class III 
(n=1689) 
Total 
(n=12,725) 
Demographics      
Age (yrs), Mean (SD) 60.2 (13.3) 59.8 (13.7) 58.7 (13.6) 57.9 (13.9) 56.0 (14.2) 58.6 (13.8) 
Gender, No. (%)       
Male 1165 (70) 1799 (60) 1792 (48) 1058 (40) 531 (31) 6345 (50) 
Female 500 (30) 1223 (40) 1920 (52) 1579 (60) 1158 (69) 6380 (50) 
Townsend deprivation index, No. (%)      
Least deprived 372 (23) 653 (23) 710 (20) 503 (20) 316 (20) 2554 (20) 
2nd quintile 336 (21) 612 (21) 716 (20) 505 (20) 302 (19) 2471 (19) 
3rd quintile 358 (22) 598 (21) 804 (23) 559 (22) 358 (22) 2677 (21) 
4th quintile 307 (19) 604 (21) 763 (21) 548 (22) 348 (22) 2570 (20) 
Most deprived 229 (14) 412 (14) 574 (16) 419 (17) 284 (18) 1918 (15) 
Age categories. No (%)       
18 to 39 years 141 (9) 261 (9) 405 (11) 332 (13) 258 (15) 1397 (11) 
40 to 59 years 675 (41) 1199 (40) 1465 (40) 1042 (40) 753 (45) 5134 (41) 
60 to 79 years 743 (45) 1377 (46) 1629 (44) 1149 (44) 616 (37) 5514 (43) 
80 years and above 106 (6) 185 (6) 213 (6) 114 (4) 62 (4) 680 (5) 
       
Clinical covariates, Mean (SD)      
HbA1c (%) 8.6 (1.9) 8.6 (1.8) 8.7 (1.8) 8.8 (1.9) 8.8 (1.8) 8.7 (1.8) 
BMI (kg/m2) 21.8 (2.8) 27.7 (1.4) 32.5 (1.4) 37.2 (1.4) 44.1 (4.3) 32.7 (6.9) 
Height (m) 1.7 (0.09) 1.7 (0.10) 1.7 (0.1) 1.7 (0.1) 1.6 (0.1) 1.7 (0.1) 
Weight (Kg) 69.7 (12.2) 81.0 (11.6) 90.5 (12.1) 100.9 (13.1) 116.4 (16.3) 91.5 (18.8) 
DBP (mmHg) 75.6 (11.1) 76.3 (10.9) 76.3 (10.6) 77.1 (11.0) 77.6 (10.7) 76.6 (10.9) 
SBP (mmHg) 134.4 (23.3) 135.0 (22.9) 135.8 (23.0) 137.2 (22.8) 138.7 (23.4) 136.1 (23.1) 
TC (mmol/l) 4.5 (1.4) 4.6 (1.3) 4.6 (1.3) 4.6 (1.3) 4.6 (1.3) 4.6 (1.3) 
Triglyceride (mmol/L) 1.8 (1.2) 2.0 (1.2) 2.0 (1.2) 2.1 (1.2) 2.2 (1.2) 2.0 (1.2) 
LDL (mmol/l) 2.4 (1.1) 2.4 (1.1) 2.4 (1.1) 2.4 (1.1) 2.4 (1.1) 2.4 (1.1) 
HDL (mmol/l) 1.3 (0.5) 1.3 (0.4) 1.3 (0.4) 1.2 (0.5) 1.2 (0.4) 1.3 (0.5) 
Albumin (g/L) 4.1 (0.4) 4.1 (0.4) 4.1 (0.4) 4.0 (0.4) 4.0 (0.4) 4.1 (0.4) 
ACR (mg/mol) 4.7 (8.2) 5.6 (8.5) 5.6 (8.4) 5.9 (8.6) 6.0 (8.5) 5.6 (8.5) 
eGFR (mls/min/1.73m2) 66.4 (20.9) 65.2 (20.9) 65.1 (21.1) 64.6 (21.5) 64.3 (21.5) 65.1 (21.2) 
Diabetes duration (yrs) 3.9 (5.0) 3.7 (5.0) 3.9 (5.0) 3.7 (4.6) 3.8 (4.6) 3.8 (4.9) 
Lifestyle        
Smoking status, No. (%)       
Non-smoker 812 (49) 1536 (51) 2005 (54) 1403 (53) 930 (55) 6686 (52) 
Ex-smoker 570 (34) 1050 (35) 1179 (32) 840 (32) 538 (32) 4177 (33) 
Current smoker 283 (17) 436 (14) 528 (14) 394 (15) 221 (13) 1862 (15) 
Alcohol status, No. (%)       
Non-drinker 453 (27) 880 (29) 1225 (33) 898 (34) 589 (35) 4045 (32) 
Ex-drinker 194 (12) 362 (12) 409 (11) 310 (12) 178 (11) 1453 (11) 
Current drinker 1018 (61) 1780 (59) 2078 (56) 1429 (54) 922 (55) 7227 (57) 
       
GLTs, No. (%)      
    Insulin       
          Premix 978 (59) 1783 (59) 2206 (59) 1470 (56) 933 (55) 7370 (58) 
          Basal-bolus 687 (41) 1239 (41) 1506 (41) 1167 (44) 756 (45) 5355 (42) 
    Metformin 1308 (79) 2496 (83) 3164 (85) 2333 (88) 1530 (91) 10831 (85) 
    Sulphonylurea 1212 (73) 2186 (72) 2728 (73) 1952 (74) 1246 (74) 9324 (73) 
    Thiazolidinediones 491 (29) 891 (29) 1172 (32) 878 (33) 622 (37) 4054 (32) 
    GLP-1RA 159 (10) 281 (9) 431 (12) 371 (14) 289 (17) 1531 (12) 
    Gliptins 220 (13) 412 (14) 545 (15) 391 (15) 273 (16) 1841 (15) 
    SGLT-2i 6 (0) 19 (1) 16 (0) 18 (1) 12 (1) 71 (1) 
    Glinides 70 (4) 116 (4) 176 (5) 115 (4) 85 (5) 562 (4) 
       
Use of Medications, No. (%)      
Aspirin 1572 (90) 2859 (92) 3519 (98) 2488 (96) 1584 (96) 12022 (94) 
Antihypertensive 1337 (85) 2498 (87) 3114 (88) 2183 (88) 1406 (89) 10538 (83) 
LLTs 1391 (88) 2566 (90) 3187 (91) 2238 (90) 1425 (90) 10807 (85) 
       
Comorbidities, No. (%)c      
    CHD 196 (12) 380 (13) 447 (12) 277 (11) 165 (10) 1465 (12) 
    PAD 116 (7) 212 (7) 263 (7) 143 (5) 89 (5) 2137 (17) 
    Heart Failure 90 (5) 167 (6) 205 (6) 141 (5) 110 (7) 713 (6) 
    Hypoglycaemia 286 (17) 500 (17) 670 (18) 445 (17) 236 (14) 2137 (17) 
    CKD (eGFR <60mls/min/1.73m2) 632 (12) 1207(24) 1479(29) 1075(21) 702(14) 5095 (40) 
       
Abbreviations: 
BMI (body mass index); SBP (systolic blood pressure); DBP (diastolic blood pressure); HbA1c (haemoglobin A1c); HDL (high-density lipoprotein); LDL (low-
density lipoprotein); TC (total cholesterol); eGFR (estimated glomerular filtration rate); LLTs (lipid lowering therapies); PAD (peripheral arterial disease); 
CHD (coronary heart disease); CKD (Chronic Kidney Disease); ACR (albumin creatinine ratio); GLTs (Glucose-lowering therapies); AMI (Acute myocardial 
infarction);  SD (standard deviation). Diabetes duration is the time from first diagnosis of diabetes to date of insulin initiation (index date); GLP-1 (Glucagon like 
peptide-1); SGLT (sodium glucose co-transporter) 
Table 2 - Proportions and odds of achieving the NICE target HbA1c of ≤7.5% (58 mmol/mol) by the BMI categories. 
 
 6 months 12 months 24 months 36 months 48 months 
 
60 months 
 
BMI 
categories at 
baseline 
Prop 
(%) 
aOR* 
(95%CI) 
Prop 
(%) 
aOR* 
(95%CI) 
Prop 
(%) 
aOR* 
(95%CI) 
Prop 
(%) 
 
aOR* 
(95%CI) 
 
Prop 
(%) 
aOR* 
(95%CI) 
Prop 
(%) 
aOR* 
(95%CI) 
Normal 36.6 
 
ref 
 
37.0 
 
ref 
 
34.2 
 
ref 
 
34.1 ref 44.8 
 
ref 
 
45.6 
 
ref 
 
Overweight 32.8 
 
0.86 
(0.75-0.98) 
 
33.1 
 
0.85 
(0.75-0.97) 
 
31.0 
 
0.87 
(0.76-0.99) 
 
32.2 
 
0.95 
(0.83-1.08) 
 
44.9 
 
0.99 
(0.87-1.12) 
 
44.4 
 
0.95 
(0.84-1.08) 
 
Obese 
Class I 
31.0 
 
0.80 
(0.71-0.91) 
 
31.6 
 
0.78 
(0.70-0.91) 
 
30.7 
 
0.87 
(0.77-0.99) 
 
33.2 
 
1.01 
(0.88-1.15) 
 
45.7 
 
1.00 
(0.89 -1.14) 
 
45.9 
 
0.98 
(0.86-1.10) 
 
Obese 
Class II 
30.0 
 
0.78 
(0.68-0.90) 
 
31.6 
 
0.81 
(0.70-0.93) 
 
29.4 
 
0.83 
(0.72-0.95) 
 
31.4 
 
0.95 
(0.83-1.10) 
 
47.6 
 
1.08 
(0.95-1.23) 
 
45.2 
 
0.93 
(0.82-1.06) 
 
Obese 
Class III 
27.8 
 
0.69 
(0.59-0.80) 
 
30.0 
 
0.73 
(0.62-0.85) 
 
30.9 
 
0.91 
(0.78-1.06) 
 
32.5 
 
1.03 
(0.88-1.21) 
 
47.1 
 
1.07 
(0.93-1.24) 
 
46.4 
 
0.99 
(0.85-1.14) 
 
 
p < 
0.0001** 
LRT 
p-value*** 
0.0001 
p < 
0.0001 
LRT 
p-value 
0.0011 
p = 
0.023 
LRT 
p-value 
0.2519 
p = 0.377 
LRT 
p-value 
0.6366 
p = 0.160 
LRT 
p-value 
0.4653 
p = 0.942 
LRT 
p-value 
0.8255 
Abbreviations: BMI (body mass index); Prop (Proportion in %);  
*aOR = Adjusted Odds Ratio. Adjusted for age, duration of diabetes, gender, socioeconomic status (measured by Townsend Deprivation scores); smoking status, diastolic and systolic blood pressure 
and insulin-regimen 
** p-value of the proportions at the follow-up timeline 
***LRT (Likelihood Ratio Test) p-value showing  
p-value for trend <0.0001 and 0.001 at 6 and 12 months respectively but not significant ( >0.05) at 24, 36, 48 and 60 months 
Table 3 - Mean follow-up BMI and mean coefficients of change in BMI compared to the normal BMI category 
 
 6 months 12 months 24 months 36 months 48 months 
 
60 months 
 
BMI categories 
at baseline 
Mean 
BMI 
(kg/m2) 
Coefff* 
(95%CI) 
Mean 
BMI 
(kg/m2) 
Coefff* 
(95%CI) 
Mean 
BMI 
(kg/m2) 
Coefff* 
(95%CI) 
Mean 
BMI 
(kg/m2) 
Coefff* 
(95%CI) 
Mean 
BMI 
(kg/m2) 
Coefff* 
(95%CI) 
Mean 
BMI 
(kg/m2) 
Coefff* 
(95%CI) 
Normal 22.7 
 
ref 
 
23.3 
 
ref 
 
25.3 
 
ref 
 
26.2 ref 26.8 
 
ref 
 
28.2 
 
ref 
 
Overweight 28.0 
 
-0.52 
(-0.65, -0.39) 
 
28.3 
 
-0.77 
(-0.96, -0.59) 
 
29.2 
 
-1.93 
(-2.28, -1.59) 
 
29.6 
 
-2.52 
(-2.90, -2.14) 
 
29.9 
 
-2.95 
(-3.35, -2.56) 
 
30.5 
 
-3.72 
(-4.12, -3.31) 
 
Obese 
Class I 
32.6 
 
-0.78 
(-0.90, -0.65) 
 
32.5 
 
-1.38 
(-1.56, -1.21) 
 
32.4 
 
-3.83 
(-4.17, -3.50) 
 
32.3 
 
-4.88 
(-5.25, -4.51) 
 
32.2 
 
-5.65 
(-6.04, -5.27) 
 
32.7 
 
-6.59 
(-6.99, -6.20) 
 
Obese 
Class II 
37.0 
 
-1.03 
(-1.17, -0.90) 
 
36.8 
 
-1.84 
(-2.03, -1.65) 
 
36.0 
 
-4.94 
(-5.30, -4.59) 
 
35.7 
 
-6.33 
(-6.72, -5.93) 
 
35.1 
 
-7.66 
(-8.07, -7.25) 
 
35.2 
 
-9.11 
(-9.53, 8.69) 
 
Obese 
Class III 
43.7 
 
-1.33 
(-1.48, -1.18) 
 
43.0 
 
-2.64 
(-2.85, -2.43) 
 
41.1 
 
-6.92 
(-7.32, -6.52) 
 
40.0 
 
-9.03 
(-9.47, -8.58) 
 
38.5 
 
-11.18 
(-11.6, -10.7) 
 
38.4 
 
-12.89 
(-13.4, -12.42) 
 
  
LRT 
p-value** 
<0.00001 
 
LRT 
p-value 
0.00001 
 
LRT 
p-value 
<0.00001 
 
LRT 
p-value 
<0.00001 
 
LRT 
p-value 
<0.00001 
 
LRT 
p-value 
<0.00001 
Abbreviations: BMI (body mass index) 
*Mean coefficient of change ion BMI compared to the normal BMI category 
**LRT (Likelihood Ratio Test) p-value showing the mean changes in BMI according to baseline BMI categories 
p-value for trend <0.0001 for each follow up timeline 
Table 4: Events, rates and hazard ratios of composite MACE and subgroup of all-cause mortality, non-fatal MI and stroke by baseline BMI 
categories. 
 
Normal 
(n=1665) 
Overweight 
(n=3022) 
Obese Class I 
(n=3712) 
Obese Class II 
(n=2637) 
Obese Class III 
(n=1689) 
Total 
(n=12,725) 
Composite Outcomea       
        No of events/person-years 143/6,508 284/11,694 320/14,542 201/10,275 147/6,495 1095/49,516 
        Composite event ratesb (95%CI) 22.0 (18.6 – 25.9) 24.3 (21.6 – 27.3) 22.0 (19.7 – 24.6) 19.6 (17.0 – 22.5) 22.6 (19.3 – 26.6) 22.1 (20.8 – 23.5) 
       Adjusted HRc (95%CI) ref 1.10 (0.90 – 1.35) 1.05 (0.86 – 1.29) 1.03 (0.83 – 1.29) 1.30 (1.02 – 1.66) - 
       
Composite Cardiovascular eventd      
        No of events/person-years 70/6510 143/11,701 150/14,549 81/10,280 56/6,499 500/49,541 
        CV event ratesb (95%CI) 10.8 (8.5 – 13.6) 12.2 (10.4 – 14.4) 10.3 (8.8 – 12.1) 7.9 (6.3 – 9.8) 8.6 (6.6 – 11.2) 10.1 (9.2 – 11.0) 
       Adjusted HRc (95%CI) ref 1.25 (0.86 – 1.81) 1.21 (0.73 – 2.02) 0.99 (0.49 – 1.97) 1.34 (0.53 – 3.40) - 
       
All-cause mortality       
        No of events/person-years 73/6,667 141/12,007 169/14,868 119/10,445 90/6,612 592/50,601 
        Mortality ratesb (95%CI) 10.9 (8.7 – 13.8) 11.7 (10.0 – 13.8) 11.4 (9.8 – 13.2) 11.4 (9.5 – 13.6) 13.6 (11.1 – 16.7) 11.7 (10.8 – 12.7) 
       Adjusted HRc (95%CI) ref 1.09 (0.81 – 1.45) 1.12 (0.84 – 1.49) 1.31 (0.96 – 1.77) 1.75 (1.26 – 2.43) - 
       
Non-fatal Acute Myocardial Infarction (AMI)      
        No of events/person-years 13/6,639 21/11,960 20/14,828 8/10,434 3/6,610 65/50,472 
        AMI event ratesb (95%CI) 2.0 (1.1 – 3.4) 1.8 (1.1 – 2.7) 1.3 (0.9 – 2.1) 0.8 (0.4 – 1.5) 0.5 (0.1 – 1.4) 1.3 (1.0 – 1.6) 
       Adjusted HRc (95%CI) ref 1.40 (0.51 – 3.84) 2.24 (0.53 – 9.48) 1.76 (0.23 – 13.3) 2.94 (0.19 – 46.0) - 
       
Non-fatal Stroke       
        No of events/person-years 57/6,541 122/11,755 130/14,597 73/10,295 53/6,505 435/49,695 
        Stroke event ratesb (95%CI) 8.7 (6.7 – 11.3) 10.4 (8.7 – 12.4) 8.9 (7.5 – 10.6) 7.1 (5.6 – 8.9) 8.1 (6.2 – 10.7) 8.8 (8.0 – 9.6) 
       Adjusted HRc (95%CI) ref 1.25 (0.84 – 1.87) 1.13 (0.66 – 1.95) 0.92 (0.45 – 1.92)                 1.17 (0.44 – 3.16) - 
       
a Composite outcome is a three-point MACE including all-cause mortality, non-fatal acute myocardial infarction (AMI) and non-fatal stroke. 
b Rates at 1000 person-years. 95%CI – 95% confidence interval. 
c aHR (Adjusted Hazard Ratio). Adjusted for age, gender, use of lipid-lowering therapies, use of antihypertensives, comorbidities of heart failure and coronary heart disease at baseline, albumin, glomerular 
filtration rate, lipid profile (total cholesterol, low density lipoprotein, high density lipoprotein and triglyceride) and use of glucagon-like peptide receptor analogues (GLP-1RA) at baseline. 
d Composite Cardiovascular event is a two-point event of non-fatal acute myocardial infarction (AMI) and non-fatal stroke. 
 
